| Title : More Positive Trial Results for Teriflunomide in MS |
| Desc : Topline results of a third phase 3 trial, TOWER, showed reductions in relapse rate and sustained disability with oral teriflunomide in relapsing MS. <br /> <i></i>Medscape Medical News |
|
